…here is a [hypothetical] scenario no one else has broached: what if the FDA approves both m-copaxone and t-lovenox on the same day! I think MNTA share price skyrockets once the market actually takes into account what just happened with Copaxone…
Agreed—in your wildly unlikely scenario, MNTA’s share price would go up substantially, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.